盆腔炎性疾病后遗症（慢性盆腔炎）是影响女性健康的疾病之一，其病势绵延给患者造成较大的经济负担。在治疗盆腔炎性疾病后遗症（慢性盆腔炎）药物中，中药是重要组成部分。但由于缺乏“中药治疗盆腔炎性疾病后遗症（慢性盆腔炎）循证药物经济学评价技术要点”，导致在对中药进行药物经济学评价过程中出现样本选取、研究方法、研究角度、成本选取、效果效用指标确立等诸多不规范现象。因此，“中药治疗盆腔炎性疾病后遗症（慢性盆腔炎）循证药物经济学评价技术要点”的制定对中药治疗盆腔炎性疾病后遗症（慢性盆腔炎）规范性至关重要。

Pelvic inflammatory disease sequela (chronic pelvic inflammation) is one of the diseases that affect women's health conditions, and leads to large economic burden. Chinese Material Medica (CMM) plays an important role in treating pelvic inflammatory disease sequela (chronic pelvic inflammatory). However, due to the lack of Evidence -based Pharmacoeconomic Evaluation Technical Essentials of CMM in Treatment of Pelvic Inflammatory Disease Sequela (Chronic Pelvic Inflammatory), non-standard phenomenon often appears in the research literature, such as the selection of research methods, viewpoint of research, determination of cost, effect and utility. Thus, the publish of Evidence -based Pharmacoeconomic Evaluation Technical Essentials of CMM in Treatment of Pelvic Inflammatory Disease Sequela (Chronic Pelvic Inflammatory) is essential for the pharmacoeconomic evaluation of CMM in treating pelvic inflammatory disease sequela (chronic pelvic inflammatory).